F-18-DOPA PET/CT changes management plan for brain tumor patients

March 9, 2012

Imaging amino acid transporters with PET/CT significantly alters intended management plans for patients with brain tumors, according to research in the March issue of The Journal of Nuclear Medicine. As a result of imaging with the radiopharmaceutical 3,4-dihydroxy-6-F-18-fluoro-L-phenylalanine (F-18-DOPA), referring physicians changed the intended management plan for 41 percent of patients with brain tumors.